Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2287)	2/26/2008 10:17:51 AM
From: Jibacoa	Respond to of 3722

DNA stock price hasn't been affected much after announcing that the U.S. Patent Office rejected a patent that protects ways it makes some antibodies by recombinant DNA technology. The stock doesn't want to close yesterday's UG. bigcharts.marketwatch.com DNA said it may appeal,it receives royalties on products covered by one or more claims of the patent, also known as Cabilly or the "415 patent". Of course, DNA has been helped lately by the decision of the FDA to approve Avastin for breast cancer,which went against the recommendation of its outside advisory panels. That decision has also helped DNDN stock, which hopes that a more flexible FDA may approve Provenge, last rejected in May in spite that an advisory committee determined that the drug was "safe and effective".<g> DNA is trying to get off from its longer term DT coming from its Dec 2005 H at $100.30 bigcharts.marketwatch.com Bernard